Silence Therapeutics
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
Corporate information
- Company entity
- Silence Therapeutics
- Headquarters / principal office
- LondonSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 1994 (listed legal predecessor); renamed 2007 ↗
- Ownership / capital status
- Publicly tradedPublicly traded (Nasdaq: SLN); public-market transactions tracked separately ↗
- Official corporate reference
- https://www.silence-therapeutics.com/our-technology/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Silence Therapeutics — official disclosure
- Company-managed LinkedIn profile — self-reported location
- Founding / incorporation disclosure — scope stated in field